Following approval by GMMMG, GM CEGC and GM Chief Officers, this commissioning statement regarding the staged implementation of NICE TA1026: Tirzepatide for managing overweight and obesity across primary care in Greater Manchester is now available to view.
To access the document please visit the medicines and devices recommendations page